Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance

Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Seminars in immunology 2017-04, Vol.30, p.67-80
Hauptverfasser: Campana, Raffaela, Huang, Huey-Jy, Freidl, Raphaela, Linhart, Birgit, Vrtala, Susanne, Wekerle, Thomas, Karaulov, Alexander, Valenta, Rudolf
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 80
container_issue
container_start_page 67
container_title Seminars in immunology
container_volume 30
creator Campana, Raffaela
Huang, Huey-Jy
Freidl, Raphaela
Linhart, Birgit
Vrtala, Susanne
Wekerle, Thomas
Karaulov, Alexander
Valenta, Rudolf
description Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.
doi_str_mv 10.1016/j.smim.2017.08.017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942701415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044532317300696</els_id><sourcerecordid>1942701415</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJaT7aP9BD0LEXOyPLX4JeypI0gYVAyKkXMZbGrRbbciTvwv77yuy2x1zmHZhnXmZexr4KyAWI-m6Xx9GNeQGiyaHNk3xgVwJUnclatBdrX5ZZJQt5ya5j3AGALFvxiV0WrZJKtuqK_Xoh48fOTTgtHIeBwm-aOE6WzzQvzlLWYSTLcZ6DR_OHIu99OJNHPgc60LQ4P_HuyH3AgS8-jXAy9Jl97HGI9OWsN-z14f5185htn38-bX5sM1MCLFnVFlTXVdVB0WCHqbO1RdukSp0SnYGmQURlhYIee6nAFm2TZr20CpW8Yd9OtunAtz3FRY8uGhoGnMjvoxaqLBoQpagSWpxQE3yMgXo9BzdiOGoBeo1U7_QaqV4j1dDqJGnp9uy_70ay_1f-ZZiA7yeA0pMHR0FH4ygFYF0gs2jr3Xv-fwHfq4ny</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1942701415</pqid></control><display><type>article</type><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</creator><creatorcontrib>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</creatorcontrib><description>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2017.08.017</identifier><identifier>PMID: 28939389</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration, Oral ; Allergen ; Allergen-specific immunotherapy ; Allergens - genetics ; Allergens - immunology ; Allergens - therapeutic use ; Allergy ; Allergy prevention ; Animals ; Humans ; Hypersensitivity - immunology ; Hypersensitivity - therapy ; Immune Tolerance ; Immunodominant Epitopes - genetics ; Immunoglobulin E - metabolism ; Oral tolerance induction ; Peptides - genetics ; Peptides - therapeutic use ; Recombinant allergen ; Recombinant Proteins - genetics ; Recombinant Proteins - therapeutic use ; T cell peptides</subject><ispartof>Seminars in immunology, 2017-04, Vol.30, p.67-80</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</citedby><cites>FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.smim.2017.08.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28939389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Campana, Raffaela</creatorcontrib><creatorcontrib>Huang, Huey-Jy</creatorcontrib><creatorcontrib>Freidl, Raphaela</creatorcontrib><creatorcontrib>Linhart, Birgit</creatorcontrib><creatorcontrib>Vrtala, Susanne</creatorcontrib><creatorcontrib>Wekerle, Thomas</creatorcontrib><creatorcontrib>Karaulov, Alexander</creatorcontrib><creatorcontrib>Valenta, Rudolf</creatorcontrib><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</description><subject>Administration, Oral</subject><subject>Allergen</subject><subject>Allergen-specific immunotherapy</subject><subject>Allergens - genetics</subject><subject>Allergens - immunology</subject><subject>Allergens - therapeutic use</subject><subject>Allergy</subject><subject>Allergy prevention</subject><subject>Animals</subject><subject>Humans</subject><subject>Hypersensitivity - immunology</subject><subject>Hypersensitivity - therapy</subject><subject>Immune Tolerance</subject><subject>Immunodominant Epitopes - genetics</subject><subject>Immunoglobulin E - metabolism</subject><subject>Oral tolerance induction</subject><subject>Peptides - genetics</subject><subject>Peptides - therapeutic use</subject><subject>Recombinant allergen</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>T cell peptides</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVJaT7aP9BD0LEXOyPLX4JeypI0gYVAyKkXMZbGrRbbciTvwv77yuy2x1zmHZhnXmZexr4KyAWI-m6Xx9GNeQGiyaHNk3xgVwJUnclatBdrX5ZZJQt5ya5j3AGALFvxiV0WrZJKtuqK_Xoh48fOTTgtHIeBwm-aOE6WzzQvzlLWYSTLcZ6DR_OHIu99OJNHPgc60LQ4P_HuyH3AgS8-jXAy9Jl97HGI9OWsN-z14f5185htn38-bX5sM1MCLFnVFlTXVdVB0WCHqbO1RdukSp0SnYGmQURlhYIee6nAFm2TZr20CpW8Yd9OtunAtz3FRY8uGhoGnMjvoxaqLBoQpagSWpxQE3yMgXo9BzdiOGoBeo1U7_QaqV4j1dDqJGnp9uy_70ay_1f-ZZiA7yeA0pMHR0FH4ygFYF0gs2jr3Xv-fwHfq4ny</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Campana, Raffaela</creator><creator>Huang, Huey-Jy</creator><creator>Freidl, Raphaela</creator><creator>Linhart, Birgit</creator><creator>Vrtala, Susanne</creator><creator>Wekerle, Thomas</creator><creator>Karaulov, Alexander</creator><creator>Valenta, Rudolf</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</title><author>Campana, Raffaela ; Huang, Huey-Jy ; Freidl, Raphaela ; Linhart, Birgit ; Vrtala, Susanne ; Wekerle, Thomas ; Karaulov, Alexander ; Valenta, Rudolf</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-582e6655b027aba655d6dad7d6deb91bc077aaa9d190faf390d287debf3d9a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Allergen</topic><topic>Allergen-specific immunotherapy</topic><topic>Allergens - genetics</topic><topic>Allergens - immunology</topic><topic>Allergens - therapeutic use</topic><topic>Allergy</topic><topic>Allergy prevention</topic><topic>Animals</topic><topic>Humans</topic><topic>Hypersensitivity - immunology</topic><topic>Hypersensitivity - therapy</topic><topic>Immune Tolerance</topic><topic>Immunodominant Epitopes - genetics</topic><topic>Immunoglobulin E - metabolism</topic><topic>Oral tolerance induction</topic><topic>Peptides - genetics</topic><topic>Peptides - therapeutic use</topic><topic>Recombinant allergen</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>T cell peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campana, Raffaela</creatorcontrib><creatorcontrib>Huang, Huey-Jy</creatorcontrib><creatorcontrib>Freidl, Raphaela</creatorcontrib><creatorcontrib>Linhart, Birgit</creatorcontrib><creatorcontrib>Vrtala, Susanne</creatorcontrib><creatorcontrib>Wekerle, Thomas</creatorcontrib><creatorcontrib>Karaulov, Alexander</creatorcontrib><creatorcontrib>Valenta, Rudolf</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campana, Raffaela</au><au>Huang, Huey-Jy</au><au>Freidl, Raphaela</au><au>Linhart, Birgit</au><au>Vrtala, Susanne</au><au>Wekerle, Thomas</au><au>Karaulov, Alexander</au><au>Valenta, Rudolf</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2017-04</date><risdate>2017</risdate><volume>30</volume><spage>67</spage><epage>80</epage><pages>67-80</pages><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28939389</pmid><doi>10.1016/j.smim.2017.08.017</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1044-5323
ispartof Seminars in immunology, 2017-04, Vol.30, p.67-80
issn 1044-5323
1096-3618
language eng
recordid cdi_proquest_miscellaneous_1942701415
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Administration, Oral
Allergen
Allergen-specific immunotherapy
Allergens - genetics
Allergens - immunology
Allergens - therapeutic use
Allergy
Allergy prevention
Animals
Humans
Hypersensitivity - immunology
Hypersensitivity - therapy
Immune Tolerance
Immunodominant Epitopes - genetics
Immunoglobulin E - metabolism
Oral tolerance induction
Peptides - genetics
Peptides - therapeutic use
Recombinant allergen
Recombinant Proteins - genetics
Recombinant Proteins - therapeutic use
T cell peptides
title Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A18%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20allergen%20and%20peptide-based%20approaches%20for%20allergy%20prevention%20by%20oral%20tolerance&rft.jtitle=Seminars%20in%20immunology&rft.au=Campana,%20Raffaela&rft.date=2017-04&rft.volume=30&rft.spage=67&rft.epage=80&rft.pages=67-80&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2017.08.017&rft_dat=%3Cproquest_cross%3E1942701415%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1942701415&rft_id=info:pmid/28939389&rft_els_id=S1044532317300696&rfr_iscdi=true